ClinicalTrials.gg
RecruitingNCT05813730C-RexUpdated Oct 22, 2026

Urinary Creatinine Excretion Time in the Neonatal Period

An interventional study of urinary creatinine excretion measurement in Renal Function, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged Up to 3 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
Up to 3 Days
Sex
All
01

Study summary

Newborn's renal function is difficult to assess and its physiology during the first days of life is still incompletely known. Studies suggest that the newborn almost completely reabsorbs creatinine during the first 48 to 72 hours of life, while at the same time it continues to produce its own creatinine. Therefore, the initial stock of creatinine at birth still increases through this production and the non or weak clearance. A better knowledge of renal physiopathology in newborns would allow to improve the therapeutic management of the infants, particularly in case of potential nephrotoxicity. No study has attempted to assess the increase in urinary creatinine excretion in neonates from a given time.

Objectives: To show when urinary creatinine excretion in newborns is efficient. Results: this study mightr show an inflection point in urinary creatinine excretion illustrating the postnatal age when renal function becomes efficient.

02

Conditions studied

  • Renal Function

Keywords

  • Newborn
  • Renal Function
  • Physiology
03

In context

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 3 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All full-term newborns (37WA or more)
  • From a physiological and spontaneous pregnancy
  • Good neonatal adaptation (Apgar 7 at 5 minutes of life)
  • Eutrophic (weight > 10th percentile and \< 90th percentile)

Exclusion criteria

Exclusion Criteria:

  • Newborns for whom no urine sample is interpretable
  • Those with a significant clinical-biological anomaly
  • Neonates with hemodynamic disorders such as low blood pressure (median \< gestational age) or hypovolemia (shock, signs of dehydration, need for volume expansion) during the first 3 days of life
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Healthy neonates

    A single arm evaluating creatinine renal excretion in healthy neonates' urine

    Other: urinary creatinine excretion measurement

Interventions

  • Otherurinary creatinine excretion measurement

    Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.

06

What researchers measure

Primary outcomes

  1. Longitudinal changes in urinary creatinine excretion in newborns

    Urine samples will be collected at each diaper change from birth until discharge

    Time frame: Longitudinal changes of collected samples from birth until discharge from the maternity hospital (i.e. from birth up to 72 hours postnatal age)

07

Study locations

1 of 1 sites recruiting
  • Maternite Regionale Universitaire CHRU NANCY
    Nancy, Lorraine 54035, France
    Recruiting
    • Jean-Michel HASCOET, MD · Contact+33 383 342 934
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Nov 2025 → Jun 2027 and completion Dec 2025 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 14, 2023
StartActual
Oct 30, 2024
Primary completionEst.
Jun 2027was Nov 2025
CompletionEst.
Sep 2027was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2025→Jun 2027
Oct 22, 2026
Study completion
Dec 2025→Sep 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Nov 2025→Jun 2027
    Study completion Dec 2025→Sep 2027
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05813730
Responsible party
Jean-Michel HASCOET (Professor, Central Hospital, Nancy, France) — Principal investigator
First posted
Apr 14, 2023
Start date
Oct 30, 2024
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Jean-Michel HASCOET
Contact
j.hascoet@chru-nancy.fr
0383342934
Nathalie LAMIREAU
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion